logo
See A ‘Sturgeon Moon' Rise With Naked Eyes: The Night Sky This Week

See A ‘Sturgeon Moon' Rise With Naked Eyes: The Night Sky This Week

Forbesa day ago
Each Monday, I pick out North America's celestial highlights for the week ahead (which also apply to mid-northern latitudes in the Northern Hemisphere). Check my main feed for more in-depth articles on stargazing, astronomy, eclipses and more.
The Night Sky This Week: August 4-10, 2025
August is one of the best months of the year for stargazing in the Northern Hemisphere, with warm evenings, lengthening nights and the appearance of the Milky Way right after dark. The latter will take a back seat this week because of a full moon — the sturgeon moon — rising into summer skies at dusk and shining much of the night. Here's everything you need to know about stargazing and astronomy this week:
Friday, August 8: See The 'Sturgeon Moon' Rising
Tonight's nearly full moon rises in the east at dusk, shining an orange, then yellow hue as it climbs into the evening sky. Named the sturgeon moon, this full phase offers a beautiful sight just after sunset. It's the perfect opportunity to get somewhere with a low view of the horizon and enjoy a magical moonrise moment.
Saturday, August 9: A Second 'Sturgeon Moon' Rising
Although it was best seen last night, there's another chance tonight. The moon actually turns full at 3:56 a.m. EDT, and will rise shortly after sunset, giving stargazers another chance to see it glowing orange on the eastern horizon.
Star of The Week: Arcturus
Arcturus, in the constellation Boötes, is one of the most famous stars of summer in the Northern Hemisphere. You'll find it shining in the west and easy to find using the handle of the Big Dipper thanks to the well-known star-hop 'arc to Arcturus.' A red giant star, Arcturus, is just 37 light-years from the solar system and the fourth brightest star in the night sky.
Constellation Of The Week: Lyra
Although the moon is up this week, some of the brighter stars and constellations will remain easy pickings. One is Lyra, a small but striking constellation centered on bright star Vega — the top-left star in the vast Summer Triangle asterism found above southeast after dark this month. Look for a small parallelogram of stars near Vega. It also contains the famous Ring Nebula (M57), visible in small telescopes.
The times and dates given apply to mid-northern latitudes. For the most accurate location-specific information, consult online planetariums like Stellarium.
Wishing you clear skies and wide eyes.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

Yahoo

timean hour ago

  • Yahoo

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

Yahoo

timean hour ago

  • Yahoo

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships
Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships

Yahoo

time2 hours ago

  • Yahoo

Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships

The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong healthcare infrastructure in North America and Europe, and rising demand in Asia-Pacific, the market is poised for continued expansion, despite challenges like high R&D costs and complex regulations. Leading companies include Merck, Dynavax, and Moderna, with future growth focusing on personalized medicine, next-gen platforms, and oncology research funding. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035" report has been added to global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term immune memory and minimal side effects. Immunotherapy's success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities. The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines. Key Topics Covered: 1. Global Cancer Vaccine Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cancer Vaccine Market, by Vaccine Type, $Million, 2023-20352.1 Preventive Vaccines2.1.1 Gardasil2.1.2 HEPLISAV-B2.2 Therapeutic Vaccines2.2.1 Bacillus Calmette-Guerin (BCG)2.2.2 Sipuleucel-T (Provenge)3. Global Cancer Vaccine Market, by Technology Type, $Million, 2023-20353.1 Recombinant3.2 Cell-based3.3 Others4. Global Cancer Vaccine Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cancer Vaccine Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cancer Vaccine Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cancer Vaccine Market, by Country4.3.3.1 Japan5. Global Cancer Vaccine Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View Merck & Co., Inc., Dynavax Technologies Corporation Dendreon Pharmaceuticals LLC Moderna, Inc BioNTech SE Transgene S.A. Imugene Limited Ose-Immuno Barinthus Biotherapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store